A method for preparing health foods having aloeswood. Preparing materials in which aloeswood, Saururus chinensis, Huperzia, white tea and Houttuynia cordata Thunb are each washed, and then dried in shade, pulverized and roasted. The roasted aloeswood, Saururus chinensis, Huperzia, white tea and Houttuynia cordata Thunb are mixed at a weight ratio of 4:1:1:1:1. The brewed and distilled aloeswood, Saururus chinensis and water mixture is mixed with the maturing an aloeswood, Saururus chinensis, Huperzia, white tea and Houttuynia cordata Thunb mixture and double boiled to prepare a leachate. The prepared leachate is extracted and concentrated, and then heat-matured to remove the moisture. The heat-matured extract is cool-dried, mixed with mineral water, then heated, dried at room temperature and molded into a predetermined shape. The prepared health foods having effects in preventing absorption of heavy metals in body and excreting the same from body.

A method for preparing health foods having aloeswood. Preparing materials in which aloeswood, Saururus chinensis, Huperzia, white tea and Houttuynia cordata Thunb are each washed, and then dried in shade, pulverized and roasted. The roasted aloeswood, Saururus chinensis, Huperzia, white tea and Houttuynia cordata Thunb are mixed at a weight ratio of 4:1:1:1:1. The brewed and distilled aloeswood, Saururus chinensis and water mixture is mixed with the maturing an aloeswood, Saururus chinensis, Huperzia, white tea and Houttuynia cordata Thunb mixture and double boiled to prepare a leachate. The prepared leachate is extracted and concentrated, and then heat-matured to remove the moisture. The heat-matured extract is cool-dried, mixed with mineral water, then heated, dried at room temperature and molded into a predetermined shape. The prepared health foods having effects in preventing absorption of heavy metals in body and excreting the same from body.

The present composition provides for mitigating adverse effects of alcohol consumption. The composition includes a fructose source comprising between 5% and 75% of a total weight of the composition, a niacinamide source comprising between 0.1% and 1% of the total weight, and a glycoprotein source comprising between 0.1% and 2% of the total weight, wherein the total weight is a weight prior to inclusion with a hydrating source. The composition can be disposed in a powder or dissolved form, as part of a concentrate, and/or part of a beverage. The composition can include mixability for diluting or mixing with the liquid or beverage for user consumption and absorprtion.

The present composition provides for mitigating adverse effects of alcohol consumption. The composition includes a fructose source comprising between 5% and 75% of a total weight of the composition, a niacinamide source comprising between 0.1% and 1% of the total weight, and a glycoprotein source comprising between 0.1% and 2% of the total weight, wherein the total weight is a weight prior to inclusion with a hydrating source. The composition can be disposed in a powder or dissolved form, as part of a concentrate, and/or part of a beverage. The composition can include mixability for diluting or mixing with the liquid or beverage for user consumption and absorprtion.

Described herein are compositions for reducing body weight, reducing body fat, improving body composition and/or preventing obesity and related conditions. In certain aspects, the compositions comprise dileucine, and a pharmaceutically acceptable carrier thereof. In certain embodiments, the composition comprises dileucine and leucine. In further aspects, the dileucine is present from about 10% to 90% (w/w). In further aspects, the dileucine is present from about 20% to 80% (w/w). In further aspects, wherein the dileucine is present from about 30% to 70% (w/w). In further aspects, the dileucine is present from about 40% to 60% (w/w).

Described herein are compositions for reducing body weight, reducing body fat, improving body composition and/or preventing obesity and related conditions. In certain aspects, the compositions comprise dileucine, and a pharmaceutically acceptable carrier thereof. In certain embodiments, the composition comprises dileucine and leucine. In further aspects, the dileucine is present from about 10% to 90% (w/w). In further aspects, the dileucine is present from about 20% to 80% (w/w). In further aspects, wherein the dileucine is present from about 30% to 70% (w/w). In further aspects, the dileucine is present from about 40% to 60% (w/w).

Described herein are compositions for reducing body weight, reducing body fat, improving body composition and/or preventing obesity and related conditions. In certain aspects, the compositions comprise dileucine, and a pharmaceutically acceptable carrier thereof. In certain embodiments, the composition comprises dileucine and leucine. In further aspects, the dileucine is present from about 10% to 90% (w/w). In further aspects, the dileucine is present from about 20% to 80% (w/w). In further aspects, wherein the dileucine is present from about 30% to 70% (w/w). In further aspects, the dileucine is present from about 40% to 60% (w/w).

A method for treating the gastrointestinal or a urogenital system of a subject with prebiotic nutrients and probiotic bacteria is provided. Multi-chamber products are described which include at least two chambers wherein probiotic bacteria or human microbiome transplants are contained in one or more inner chambers and wherein prebiotic nutrients are contained in an outer chamber, the outer chamber completely enclosing the inner chamber(s). One or both chambers may contain a pharmaceutically acceptable material that is solid outside the human body when in a dry environment, but that melts at internal body temperature. The products may be administered by oral, rectal, vaginal, or urethral routes.

A method for treating the gastrointestinal or a urogenital system of a subject with prebiotic nutrients and probiotic bacteria is provided. Multi-chamber products are described which include at least two chambers wherein probiotic bacteria or human microbiome transplants are contained in one or more inner chambers and wherein prebiotic nutrients are contained in an outer chamber, the outer chamber completely enclosing the inner chamber(s). One or both chambers may contain a pharmaceutically acceptable material that is solid outside the human body when in a dry environment, but that melts at internal body temperature. The products may be administered by oral, rectal, vaginal, or urethral routes.

Compositions in homogenised powder form consisting of hydroxypropyl methylcellulose particles, and at least one chemical signalling agent in particle form, and optionally a biologically active agent, wherein the homogenised powder comprises particles having a mean particle diameter of ≥20 μm to ≤500 μmm uses and kits therefor.